Avalo Therapeutics, Inc. (AVTX)
Avalo Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Avalo Therapeutics, Inc. (AVTX) is a Biotechnology company based in US with a market capitalization of $179.1M. Revenue declined 86.6% year-over-year and free cash flow was negative at -$51.5M. This page tracks AVTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 23 employees · IPO Oct 14, 2015
Valuation
Valuation & price
$17.74as of May 17, 2026· -22.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.16
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$179.1M
Market cap
-86.6%
Revenue growth (YoY)
100.0%
Gross margin
-$51.5M
Free cash flow (USD)
-$95.9M
Net debt
Net cash position
64.9%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
10
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 13, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJun 25, 2026Filing
Insider Sell $26K · 10b5-1 PlanDoyle Mittie · Chief Medical Officer · $26.1K
- 8-K eventJun 23, 2026Filing
Director Appointment
- 8-K eventJun 16, 2026Filing
Corporate Presentation
- 8-K eventJun 12, 2026Filing
Preferred Stock Designation
- 8-K eventJun 8, 2026Filing
Employee Stock Purchase Plan
- Insider sellJun 1, 2026Filing
Insider Sell $11K · 10b5-1 PlanDoyle Mittie · Chief Medical Officer · $10.9K
- Insider sellMay 19, 2026Filing
Insider Sell $56K · 10b5-1 PlanDoyle Mittie · Chief Medical Officer · $56.3K
- 8-K eventMay 13, 2026Filing
Earnings Release
- Quarterly reportMay 13, 2026Filing
10-Q Filed
- Insider sellMay 11, 2026Filing
Insider Sell $449K · 10b5-1 PlanSullivan Christopher Ryan · Chief Financial Officer · $448.8K
Questions
Frequently asked questions
What is Avalo Therapeutics, Inc.'s market cap?
Avalo Therapeutics, Inc. (AVTX) has a market capitalization of $179.1M.
What is AVTX's P/E ratio?
A meaningful P/E ratio is not available for AVTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is AVTX's price-to-book (P/B) ratio?
AVTX trades at 2.16 times book value per share.
Are insiders buying AVTX stock?
SEC Form 4 filings show no open-market insider buys at Avalo Therapeutics, Inc. in the last 90 days (10 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.